influenza
virus
major
human
pathogen
caus
signific
number
ill
death
year
season
epidem
unit
state
alon
season
epidem
influenza
estim
result
million
outpati
visit
annual
total
econom
burden
billion
elderli
children
individu
underli
medic
condit
risk
increas
morbid
mortal
caus
influenza
viru
infect
furthermor
emerg
influenza
viru
strain
potenti
sustain
effici
humantohuman
transmiss
caus
global
pandem
recent
outbreak
influenza
term
treatment
option
neuraminidas
inhibitor
ni
current
firstlin
influenza
viru
antivir
drug
ni
administr
recommend
earli
phase
diseas
h
ill
onset
replic
influenza
viru
peak
commun
level
time
implement
patient
isol
social
distanc
measur
includ
school
closur
shown
reduc
viral
transmiss
control
influenza
viru
infect
highlight
critic
role
effici
diagnost
assay
enabl
prompt
identif
infect
person
initi
subsequ
diseas
manag
present
wide
rang
techniqu
avail
achiev
differ
level
diagnosi
includ
serolog
convent
viru
cultur
direct
fluoresc
antibodi
dfa
test
rapid
immunoassay
rapid
test
nucleic
acid
test
nat
serolog
viru
cultur
involv
lengthi
laboratori
process
day
render
method
unsuit
rapid
clinic
diagnosi
rmix
cultur
wide
use
detect
influenza
virus
improv
turnaround
time
day
dfa
although
significantli
reduc
turnaround
time
h
gener
less
sensit
viru
cultur
requir
train
personnel
perform
interpret
result
rapid
test
influenza
viru
base
viral
antigen
detect
later
flow
immunochromatograph
dipstick
assay
becom
wide
use
pointofcar
set
emerg
room
doctor
clinic
etc
rapid
test
userfriendli
perform
minim
train
without
requir
complex
equip
term
turnaround
time
rapid
test
confer
highest
effici
result
known
within
min
howev
shown
rapid
test
exhibit
inconsist
test
perform
especi
detect
virus
due
limit
rapid
immunoassay
increas
avail
molecular
technolog
number
molecular
assay
inhous
research
diagnost
use
becom
avail
major
molecular
test
base
realtim
quantit
revers
transcriptionpcr
qrtpcr
requir
train
oper
special
equip
extract
amplif
step
addit
cost
unavail
central
test
pose
signific
threat
control
influenza
viru
resourcelimit
set
describ
new
molecular
assay
detect
influenza
b
viru
nucleic
acid
develop
samba
simpl
amplificationbas
assay
molecular
platform
achiev
high
level
perform
provid
fast
easytous
diagnost
solut
test
samba
flu
duplex
test
coupl
isotherm
amplif
visual
detect
nucleic
acid
dipstick
allow
simpl
sensit
diagnosi
influenza
viru
b
infect
influenza
virus
former
season
provid
public
health
england
phe
colindal
virus
cultur
allanto
caviti
embryon
hen
egg
quantifi
plaqu
assay
heat
inactiv
min
dilut
viru
transport
medium
vtm
manufactur
phe
cell
ad
simul
clinic
sampl
well
cultur
virus
use
determin
analyt
reactiv
nation
institut
biolog
standard
control
nibsc
receiv
freezedri
format
reconstitut
follow
heat
inactiv
quantif
inhous
qrtpcr
system
use
vitro
transcript
standard
detail
describ
inactiv
cultur
dilut
pool
neg
swab
sampl
copan
univers
transport
medium
utm
copan
brescia
itali
desir
concentr
number
copiestest
sampl
rna
extract
panel
respiratori
virus
purchas
qnostic
glasgow
unit
kingdom
escherichia
coli
bacteriophag
atcc
acquir
atcc
propag
titrat
accord
supplier
instruct
total
sampl
collect
two
institut
describ
clinic
evalu
sampl
surplu
sampl
left
routin
respiratori
test
clinic
result
patient
detail
initi
blind
oper
samba
flu
duplex
test
sampl
two
group
prospect
collect
mix
nasalthroat
swab
specimen
collect
march
april
clinic
microbiolog
public
health
laboratori
health
protect
agenc
hpa
addenbrook
hospit
cambridg
unit
kingdom
ii
archiv
nasopharyng
swab
specimen
provid
scientif
institut
public
health
wivisp
brussel
belgium
sampl
submit
wivisp
test
influenza
season
posit
archiv
sampl
influenza
viru
posit
influenza
b
viru
posit
threshold
cycl
ct
ct
ct
ct
ct
ct
valu
provid
wivisp
samba
test
group
unit
kingdom
brussel
screen
confirmatori
data
retrospect
avail
quantif
cultur
stock
dilut
viru
utm
dilut
extract
use
qiaamp
viral
rna
minikit
qiagen
crawley
unit
kingdom
accord
manufactur
instruct
elut
volum
rna
transcript
contain
influenza
ab
viru
conserv
sequenc
target
samba
produc
use
quantif
cultur
virus
summari
cdna
gener
rna
extract
use
superscript
iii
firststrand
synthesi
system
rtpcr
invitrogen
paisley
unit
kingdom
amplicon
influenza
ab
viru
sequenc
chosen
target
samba
flu
duplex
test
amplifi
primer
set
influenza
viru
amf
amr
influenza
b
viru
bnsf
bnsr
flank
conserv
region
use
hot
master
taq
polymeras
prime
influenza
viru
influenza
b
viru
amplicon
purifi
use
qiaquick
pcr
purif
kit
qiagen
follow
clone
pcrii
vector
use
ta
clone
kit
dual
promot
pcrii
vector
invitrogen
influenza
ab
viru
plasmid
transform
one
shot
top
chemic
compet
e
coli
cell
invitrogen
purifi
use
qiaprep
spin
miniprep
kit
qiagen
orient
insert
confirm
sequenc
primer
forward
revers
plasmid
correct
insert
sequenc
select
produc
pcr
amplicon
use
forward
revers
primer
follow
pcr
purif
purifi
amplicon
quantifi
use
nanodrop
system
thermo
scientif
recommend
amount
amplicon
transcrib
vitro
megashortscript
kit
influenza
viru
megascript
kit
influenza
b
viru
ambion
paisley
unit
kingdom
transcript
purifi
use
megaclear
kit
ambion
concentr
determin
use
nanodrop
system
final
number
copi
per
microlit
prepar
transcript
calcul
accord
follow
formula
rna
amount
rna
concentr
weight
rna
gmol
copiesmol
influenza
ab
viru
transcript
dilut
water
serial
dilut
use
standard
qrtpcr
inhous
onestep
realtim
rtpcr
qrtpcr
assay
develop
quantif
influenza
viru
cultur
intend
use
diagnost
assay
use
rna
transcript
standard
primer
eurofin
mwg
operon
ebersberg
germani
use
follow
influenza
forward
influenza
revers
influenza
b
forward
influenza
b
revers
probe
life
technolog
warrington
unit
kingdom
use
influenza
probe
fam
mgbnfq
minorgroov
binder
nonfluoresc
quencher
influenza
b
probe
qrtpcr
perform
use
superscript
iii
platinum
onestep
qrtpcr
kit
invitrogen
qpcr
system
agil
technolog
stockport
unit
kingdom
qrtpcr
mixtur
prepar
volum
contain
influenza
viru
forward
revers
primer
influenza
viru
b
forward
revers
primer
influenza
viru
probe
influenza
viru
b
probe
dimethyl
sulfoxid
superscript
iii
rtplatinum
taq
mix
cycl
condit
start
initi
incub
min
min
follow
cycl
denatur
extens
step
min
fluoresc
signal
acquir
end
cycl
qrtpcr
chemistri
optim
use
transcript
produc
describ
previou
section
term
test
perform
method
consist
detect
copi
transcript
standard
per
reaction
mixtur
quantif
cultur
viru
rna
extract
amplifi
duplic
least
two
extract
perform
influenza
ab
viru
transcript
standard
titer
stock
viru
calcul
take
account
amplif
elut
extract
volum
clinic
specimen
collect
two
site
hpa
cambridg
wivisp
screen
independ
qualifi
biomed
scientist
presenc
influenza
viru
accord
routin
test
protocol
clinic
specimen
screen
influenza
viru
qrtpcr
assay
region
clinic
microbiolog
laboratori
cambridg
health
district
unit
kingdom
previous
report
gener
quadriplex
assay
upgrad
studi
pentaplex
assay
capabl
detect
influenza
viru
subtyp
influenza
b
viru
hemagglutinin
subtyp
bacteriophag
perform
essenti
outlin
refer
follow
modif
hemagglutinin
subtyp
primer
probe
replac
hemagglutininspecif
primer
probe
primer
concentr
probe
addit
set
hemagglutinin
primer
probe
season
influenza
viru
also
includ
name
primer
probe
concentr
respect
gener
influenza
viru
matrix
probe
replac
anoth
gener
probe
name
use
concentr
along
amf
primer
amr
primer
previous
report
report
label
influenza
b
viru
probe
bnp
probe
convert
quasar
access
fifth
channel
crimson
rotorgen
instrument
creat
pentaplex
assay
concentr
primer
bnpf
bnpr
quasar
probe
influenza
viru
b
compon
assay
howev
increas
respect
bacteriophag
intern
control
ic
compon
ident
describ
previous
primer
roxlabel
probe
concentr
pentaplex
assay
perform
use
superscript
iii
platinum
onestep
qrtpcr
enzym
invitrogen
paisley
unit
kingdom
reaction
volum
contain
mm
rotorgen
instrument
amplif
condit
incub
min
min
follow
cycl
denatur
anneal
extens
min
fluoresc
measur
five
channel
end
cycl
upgrad
pentaplex
assay
subject
program
valid
assess
perform
allow
supersed
quadriplex
assay
laboratori
frontlin
diagnost
test
briefli
routin
clinic
respiratori
specimen
compris
influenza
viru
aposit
influenza
b
virusposit
neg
specimen
process
realtim
assay
parallel
concord
result
obtain
assay
influenza
influenza
b
virusposit
specimen
neg
specimen
pentaplex
assay
provid
addit
type
data
influenza
viru
posit
ie
distinguish
isol
ct
valu
compar
compon
gener
influenza
b
virus
assay
broadli
similar
howev
sampl
gave
consist
lower
ct
valu
pentaplex
assay
perform
assay
also
assess
use
number
extern
qualiti
assess
eqa
panel
qcmd
influenza
hemagglutinin
type
eqa
program
sampl
qcmd
influenza
b
rna
eqa
program
sampl
obtain
qualiti
control
molecular
diagnost
wwwqcmdorg
annual
hpa
influenza
molecular
profici
panel
contain
sampl
also
subject
assay
parallel
assay
deliv
score
three
eqa
panel
give
concord
result
common
influenza
b
viru
compon
quadriplex
assay
howev
abl
type
sampl
pentaplex
assay
could
distinguish
type
sampl
panel
line
defin
assay
attribut
serial
dilut
rna
extract
viru
stock
asolomon
analyz
realtim
assay
limit
detect
determin
ident
analyt
sensit
pentaplex
assay
calcul
use
serial
dilut
plasmid
construct
contain
matrix
gene
nucleoprotein
gene
target
site
found
genom
equival
per
pcr
influenza
b
virus
respect
inhous
duplex
qrt
pcr
develop
simultan
detect
influenza
b
virus
qrtpcr
perform
use
superscript
iii
platinum
onestep
qrtpcr
kit
invitrogen
qpcr
system
agil
technolog
stockport
unit
kingdom
primer
probe
influenza
viru
target
matrix
gene
influenza
b
viru
target
ha
gene
qrtpcr
mixtur
prepar
reaction
volum
contain
influenza
viru
forward
revers
primer
infa
infa
rev
influenza
b
viru
forward
revers
primer
inflb
inflb
rev
influenza
viru
probe
infa
probe
influenza
b
viru
probe
inflb
superscript
iii
rtplatinum
taq
mix
cycl
condit
start
initi
incub
min
min
follow
cycl
denatur
extens
step
fluoresc
signal
acquir
end
cycl
assay
develop
use
wivisp
overse
influenza
surveil
system
belgium
qualiti
assay
control
regular
intern
extern
qualiti
assess
program
clinic
data
collect
assay
report
whoeurop
influenza
surveil
network
eurofluorg
epidemiolog
monitor
wivisp
assay
therefor
chosen
refer
test
archiv
sampl
samba
primer
probe
target
influenza
viru
conserv
region
matrix
protein
gene
influenza
viru
nonstructur
protein
gene
influenza
b
viru
design
first
analyz
avail
sequenc
segment
influenza
viru
resourc
nation
center
biotechnolog
inform
http
wwwncbinlmnihgovgenomesflufluhtml
sequenc
gene
segment
align
multipl
align
use
fast
fourier
transform
mafft
program
avail
european
molecular
biolog
bioinformat
institut
emblebi
http
wwwebiacuktoolsmsamafft
conserv
region
suitabl
samba
identifi
jalview
program
version
univers
dunde
dunde
unit
kingdom
primer
probe
target
influenza
b
viru
conserv
region
design
use
version
http
frodowimitedu
follow
minor
modif
compat
samba
oligonucleotid
analyz
silico
specif
use
basic
local
align
search
tool
blast
predict
secondari
structur
gc
content
potenti
hetero
homodim
format
use
oligoanalyz
version
integr
dna
technolog
primerprob
set
adapt
rtpcr
qrtpcr
use
product
vitro
transcript
quantif
cultur
stock
describ
analysi
influenza
ab
viru
sequenc
influenza
viru
matrix
protein
gene
influenza
b
viru
nonstructur
protein
ns
gene
identifi
suitabl
target
samba
flu
duplex
test
due
high
degre
sequenc
conserv
conserv
region
optim
target
length
gc
content
chosen
design
amplif
primerprob
set
coincident
initi
design
samba
flu
primer
overlap
cdc
univers
influenza
viru
primer
forward
revers
cdc
influenza
viru
primer
therefor
modifi
adapt
samba
one
tent
primer
set
evalu
primer
set
af
ar
amplifi
nt
target
region
influenza
viru
gene
eventu
select
influenza
b
viru
primer
set
bf
br
design
target
conserv
region
influenza
b
viru
ns
gene
wherea
ic
primer
set
icf
icr
amplifi
region
phage
genom
show
sequenc
similar
known
human
pathogen
promot
linker
sequenc
ad
end
three
revers
primer
detector
probe
label
multipl
hapten
moieti
captur
probe
design
target
region
recogn
sequenc
singlestrand
samba
product
tabl
list
oligonucleotid
design
samba
flu
duplex
test
specimen
receiv
univers
cambridg
prepar
three
aliquot
samba
test
discrep
analysi
repeat
test
necessari
aliquot
swab
sampl
extract
use
sambaprep
machin
proprietari
lysi
wash
elut
buffer
describ
previous
lysi
buffer
ad
pfu
phage
optim
input
titrat
lot
phage
cultur
maintain
effici
triplex
amplif
influenza
ab
viru
target
phage
control
dilut
utm
intern
control
isotherm
amplif
detect
step
perform
enclos
sambaamp
system
fig
detect
amplif
product
perform
previous
describ
except
process
perform
enclos
devic
data
analysi
dipstick
signal
score
neg
strong
posit
accord
inhous
score
chart
total
turnaround
time
min
pearson
productmo
correl
coeffici
r
use
compar
ct
valu
qrtpcr
product
signal
strength
samba
test
confid
interv
ci
calcul
use
vassarstat
http
vassarstatsnet
limit
detect
lod
samba
flu
duplex
test
determin
test
dilut
quantifi
cultur
viru
genom
copi
number
use
inhous
qrtpcr
spike
pool
neg
swab
specimen
lod
defin
lowest
concentr
replic
test
posit
use
repres
strain
influenza
b
virus
respect
first
copi
influenza
ab
virus
test
quadrupl
dilut
except
copi
yield
posit
concentr
copi
subsequ
test
increment
copi
replic
least
replic
test
posit
accord
procedur
lod
samba
flu
duplex
test
determin
copiestest
copiestest
influenza
b
virus
respect
panel
common
respiratori
pathogen
cultur
supernat
tabl
use
valid
analyt
specif
virus
test
neg
samba
panel
compris
influenza
virus
includ
subtyp
influenza
b
virus
test
determin
detect
spectrum
samba
flu
duplex
test
copi
number
cultur
quantifi
use
inhous
qrtpcr
assay
except
quantifi
pfu
owe
low
sampl
volum
two
hundr
copiestest
panel
member
pfutest
test
duplic
test
posit
tabl
dynam
rang
ic
analyz
test
serial
dilut
cultur
viru
pool
clinic
sampl
highest
possibl
concentr
million
copiestest
influenza
b
virus
respect
ic
signal
remain
visibl
million
copiestest
influenza
b
viru
respect
outcompet
higher
level
influenza
viru
addit
potenti
competit
inhibit
assay
evalu
use
sampl
simul
coinfect
variou
concentr
influenza
b
virus
singl
reaction
mixtur
five
hundr
copi
influenza
viru
mix
copi
influenza
b
viru
vice
versa
simul
coinfect
sampl
test
duplic
success
detect
virus
observ
two
viral
concentr
within
differ
eg
copi
differ
concentr
viru
lower
level
outcompet
intern
control
line
visibl
simul
concentr
inhous
qualiti
control
qc
panel
consist
neg
mediumposit
copiestest
lowposit
copiestest
sampl
use
valid
perform
product
lot
reagent
throughout
project
analyz
test
reproduc
panel
compos
four
replic
panel
member
influenza
viru
medium
posit
influenza
viru
low
posit
influenza
b
viru
medium
posit
influenza
b
viru
low
posit
neg
sampl
total
test
three
oper
evalu
interoper
reproduc
addit
panel
test
perform
one
oper
three
differ
day
establish
interday
reproduc
replic
test
oper
well
overal
result
replic
total
met
intern
qc
criteria
posit
neg
posit
medium
posit
least
posit
low
posit
clinic
evalu
samba
flu
duplex
test
conduct
test
sampl
two
public
health
laboratori
hpa
cambridg
unit
kingdom
wivisp
brussel
belgium
detail
clinic
sampl
describ
previou
section
brief
prospect
nasalthroat
swab
sampl
collect
winter
season
hpa
cambridg
test
fresh
tabl
archiv
nasopharyng
swab
specimen
provid
wivisp
brussel
tabl
routin
qrtpcr
assay
use
two
collabor
center
use
compar
test
compar
test
result
initi
blind
samba
result
sent
compar
refer
test
collabor
end
evalu
initi
test
samba
flu
duplex
test
detect
influenza
aposit
influenza
bposit
concord
sampl
four
sampl
test
influenza
posit
samba
neg
qrtpcr
two
sampl
test
neg
samba
influenza
b
posit
qrtpcr
ct
valu
resolv
discrep
prevent
test
bia
six
discord
sampl
blind
test
alongsid
concord
one
randomli
select
total
use
twostep
typingsubtyp
realtim
rtpcr
assay
influenza
former
season
influenza
b
virus
routin
use
influenza
surveil
phe
colindal
concord
sampl
gave
result
samba
compar
qrtpcr
phe
realtim
assay
four
influenza
viru
sambaposit
qrtpcrneg
sampl
test
neg
two
influenza
b
viru
sambaneg
qrtpcrposit
sampl
also
test
neg
summari
analysi
clinic
specimen
samba
show
resolv
clinic
sensit
specif
influenza
viru
test
sensit
specif
influenza
b
viru
test
tabl
perform
prospect
studi
although
small
sampl
size
retrospect
studi
similar
notabl
test
one
sampl
belgium
initi
gave
invalid
result
upon
repeat
sampl
test
neg
concord
gave
invalid
rate
samba
flu
duplex
test
detect
almost
posit
case
clearli
visibl
signal
even
sampl
low
viral
load
ct
six
sampl
show
low
dipstick
signal
two
low
viral
load
samba
id
samba
signal
ct
samba
id
samba
signal
ct
four
later
confirm
resolv
qrtpcr
also
retest
samba
fals
posit
possibl
due
degrad
viral
genom
origin
sampl
contamin
extract
process
weak
neg
correl
observ
signal
strength
samba
test
ct
valu
qrtpcr
assay
r
p
evolv
genet
antigen
variabl
influenza
virus
main
obstacl
manag
influenza
epidem
pandem
rapid
accur
diagnost
test
close
sourc
import
control
outbreak
detect
emerg
influenza
virus
correl
efficaci
diseas
control
earli
initi
medic
intervent
accentu
need
improv
influenza
viru
diagnost
assay
offer
easeofus
rapid
immunoassay
accuraci
molecular
technolog
recent
number
commerci
molecular
test
iquum
liat
influenza
ab
assay
simplexa
flu
ab
rsv
direct
cepheid
xpert
flu
test
design
use
nearpati
set
assay
simplifi
technic
manual
step
molecular
test
use
autom
devic
nevertheless
due
use
realtim
pcr
technolog
assay
requir
special
equip
softwar
sampl
process
data
interpret
samba
flu
duplex
test
describ
studi
util
isotherm
amplif
visual
dipstick
detect
viral
nucleic
acid
amplif
product
reduc
complex
molecular
test
intern
control
base
bacteriophag
also
integr
test
monitor
entir
test
procedur
extract
detect
analyt
assay
abl
detect
copiestest
copiesml
influenza
b
virus
respect
samba
also
demonstr
promis
clinic
perform
compar
routin
qrtpcr
use
two
nation
refer
laboratori
tabl
addit
test
shown
analyt
specif
common
respiratori
pathogen
found
reactiv
differ
subtypesstrain
influenza
ab
virus
rare
event
influenza
b
viru
coinfect
samba
flu
duplex
test
capabl
detect
virus
viral
load
within
differ
evalu
new
assay
blind
manner
directli
link
valid
claim
test
perform
inde
signific
qualiti
concern
rapid
test
influenza
viru
failur
report
whether
clinic
evalu
conduct
blind
fashion
clinic
evalu
samba
flu
duplex
test
clinic
sampl
test
blind
includ
test
archiv
sampl
wivisp
belgium
winter
england
influenza
viru
activ
low
subtyp
viru
domin
strain
outcompet
influenza
b
virus
reason
retrospect
archiv
swab
sampl
collect
wivisp
belgium
includ
betweenseason
month
use
supplement
small
number
prospect
collect
sampl
obtain
cambridg
ensur
clinic
evalu
samba
flu
duplex
test
limit
diagnosi
subtyp
total
samba
test
show
promis
perform
sensit
specif
influenza
b
virus
detect
compar
routin
qrtpcr
use
two
nation
refer
laboratori
popul
clinic
sampl
invalid
rate
ic
test
signal
requir
repeat
entir
test
procedur
found
comparison
invalid
test
due
failur
intern
control
report
sampl
prodess
proflu
assay
sampl
report
xtag
rvp
test
novelti
influenza
viru
rapid
test
featur
allow
test
result
interpret
eye
dipstick
visual
detect
intend
improv
usabl
nearpati
diagnosi
might
result
diminish
test
sensit
dipstick
signal
posit
sampl
easili
distinguish
neg
case
oper
stevenson
loeffelholz
report
weak
dipstick
signal
intens
nearli
posit
pandem
sampl
test
use
quickvu
influenza
ab
test
larg
proport
weak
posit
result
could
advers
affect
overal
test
perform
due
operatordepend
error
identifi
weak
signal
posit
principl
samba
test
take
advantag
explos
accumul
increas
h
singlestrand
amplif
product
isotherm
amplif
conjunct
fine
adjust
amplificationdetect
formul
high
yield
viral
rna
purif
achiev
allornon
signal
profil
ie
posit
test
signal
almost
alway
visibl
strong
signal
allornon
featur
reflect
weak
correl
dipstick
signal
ct
valu
r
p
samba
flu
duplex
test
greatli
minim
ambigu
test
interpret
ic
signal
samba
flu
duplex
test
neg
sampl
gave
strong
ic
signal
although
posit
sampl
gave
ic
signal
lower
ic
signal
posit
could
relat
assay
optim
favor
amplif
influenza
viru
target
order
achiev
high
test
sensit
could
remedi
retitr
input
ic
extract
step
andor
ic
primer
amplif
mix
nevertheless
ic
system
develop
effect
indic
trueneg
result
give
strong
ic
signal
presenc
ic
signal
requir
strong
influenza
virusposit
case
separ
neg
run
alway
includ
monitor
amplif
ic
term
turnaround
time
samba
flu
duplex
test
current
take
h
min
entir
test
procedur
compar
commerci
molecular
test
integr
extract
procedur
take
h
extract
amplificationdetect
samba
maintain
competit
advantag
howev
commerci
test
design
pointofcar
use
much
shorter
turnaround
time
min
hour
samba
disadvantag
could
address
reduc
detect
amplif
time
current
longer
requir
expect
test
sensit
object
reduc
turnaround
time
approxim
h
samba
capac
process
four
sampl
one
test
run
throughput
make
samba
particularli
suitabl
nearpati
set
physician
clinic
sampl
number
small
sophist
test
procedur
permit
although
samba
show
good
sensit
influenza
viru
type
sampl
would
still
need
refer
central
laboratori
subtyp
identif
case
epidemiolog
monitor
molecular
diagnosi
lateralvert
flow
system
describ
detect
viral
parasit
infect
howev
assay
lack
integr
nucleic
acid
extract
protocol
yet
demonstr
clinic
efficaci
practic
set
summari
report
molecular
influenza
viru
duplex
test
show
clinic
perform
compar
convent
qrtpcr
test
use
nation
refer
laboratori
unit
kingdom
belgium
moreov
demonstr
practic
implement
new
format
nucleic
acid
amplif
test
coupl
high
sensit
molecular
detect
low
technic
requir
data
interpret
via
dipstick
chemistri
present
integr
semiautom
platform
undergo
develop
fulli
autom
test
envisag
accur
easeofus
featur
assay
bring
stateoftheart
molecular
test
influenza
viru
closer
patient
near
futur
